Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone deacetylases (HDACs) are enzymes that remove acetyl groups from lysine residues on histones and non-histone proteins, thereby influencing chromatin structure and gene expression. Class IIb HDACs consist of two members: HDAC6 and HDAC10. HDAC6 is the main cytoplasmic deacetylase, targeting cytoskeletal proteins and playing roles in cell motility, protein degradation, stress response, and immune signaling. HDAC10 is structurally similar and may be involved in DNA repair and autophagy. Both enzymes are zinc-dependent and have become attractive therapeutic targets for cancer and neurodegenerative diseases.
Inhibition of histone deacetylase activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone Deacetylase Class IIb (HDAC Class IIb).